JP2010535504A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535504A5
JP2010535504A5 JP2010519930A JP2010519930A JP2010535504A5 JP 2010535504 A5 JP2010535504 A5 JP 2010535504A5 JP 2010519930 A JP2010519930 A JP 2010519930A JP 2010519930 A JP2010519930 A JP 2010519930A JP 2010535504 A5 JP2010535504 A5 JP 2010535504A5
Authority
JP
Japan
Prior art keywords
fragment
composition
polypeptide
seq
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010519930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535504A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/009282 external-priority patent/WO2009020553A2/en
Publication of JP2010535504A publication Critical patent/JP2010535504A/ja
Publication of JP2010535504A5 publication Critical patent/JP2010535504A5/ja
Pending legal-status Critical Current

Links

JP2010519930A 2007-08-03 2008-08-01 クラミジア抗原 Pending JP2010535504A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96321507P 2007-08-03 2007-08-03
PCT/US2008/009282 WO2009020553A2 (en) 2007-08-03 2008-08-01 Chlamydia antigens

Publications (2)

Publication Number Publication Date
JP2010535504A JP2010535504A (ja) 2010-11-25
JP2010535504A5 true JP2010535504A5 (cg-RX-API-DMAC7.html) 2012-10-11

Family

ID=40341938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010519930A Pending JP2010535504A (ja) 2007-08-03 2008-08-01 クラミジア抗原

Country Status (7)

Country Link
US (1) US20100260791A1 (cg-RX-API-DMAC7.html)
EP (1) EP2185577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010535504A (cg-RX-API-DMAC7.html)
CN (1) CN102027003A (cg-RX-API-DMAC7.html)
AU (1) AU2008284352A1 (cg-RX-API-DMAC7.html)
CA (1) CA2695421A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009020553A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
WO2009143413A1 (en) * 2008-05-22 2009-11-26 Children'smedical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
US8313894B2 (en) * 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
KR102084509B1 (ko) 2011-05-11 2020-03-05 칠드런'즈 메디컬 센터 코포레이션 변형 비오틴-결합 단백질, 그 융합 단백질 및 응용
ES3031233T3 (en) * 2012-12-28 2025-07-07 Qiagen Sciences Llc A cell mediated immune response assay
EP3601536A4 (en) 2017-03-20 2021-01-13 Genocea Biosciences, Inc. TREATMENT PROCESSES
EP3651794A1 (en) * 2017-07-13 2020-05-20 Nanobio Corporation Chlamydia nanoemulsion vaccine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP2228384A1 (en) * 1997-11-28 2010-09-15 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
KR100982204B1 (ko) * 2001-12-12 2010-09-14 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 클라미디아 트라코마티스에 대한 면역화
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
RU2352356C2 (ru) * 2003-06-26 2009-04-20 Новартис Вэксинес Энд Дайэгностикс, Инк. ИММУНОГЕННАЯ КОМПОЗИЦИЯ НА ОСНОВЕ АНТИГЕНА Chlamydia trachomatis (ВАРИАНТЫ) И ЕЕ ИСПОЛЬЗОВАНИЕ
EP1976557A2 (en) * 2005-12-22 2008-10-08 Novartis Vaccines and Diagnostics S.r.l. Chlamydial antigens
US20100310593A1 (en) * 2007-06-14 2010-12-09 Emergent Product Development Gaithersburg Inc. Vaccines Against Chlamydia Infection

Similar Documents

Publication Publication Date Title
CN116096735A (zh) 乙型冠状病毒的预防和治疗
JP2010516290A5 (cg-RX-API-DMAC7.html)
JP2010535504A5 (cg-RX-API-DMAC7.html)
JP6676661B2 (ja) ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物
CN111448208B (zh) 用于治疗和/或预防异位性皮肤炎的il-31肽免疫原及其剂型
CN110612118A (zh) 用于引起针对hbv的免疫应答的病毒样粒子
JP7146926B2 (ja) Cd4ヘルパーt細胞エピトープの融合ペプチドおよびそのワクチン
US20220073946A1 (en) Virus-like particles of cmv modified by fusion
WO2022127825A1 (zh) 针对新型冠状病毒感染的疫苗组合物
KR20150131292A (ko) 인플루엔자 핵단백질 백신
WO2016178811A1 (en) Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
Lu et al. DNA vaccine ROP 29 from Toxoplasma gondii containing R848 enhances protective immunity in mice
KR20180038557A (ko) 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도
JP2017527293A5 (cg-RX-API-DMAC7.html)
KR101881947B1 (ko) 기생충 질병에 대한 백신 또는 진단용으로 사용되는 l3 및/또는 l5 공급원의 용도
WO2023217005A1 (zh) 串联式杂合三聚体新冠疫苗
Li et al. Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice
JP2021524280A (ja) ハウスダストダニアレルギーの処置および予防
WO2019228032A1 (zh) 磷酸化多肽抗原疫苗及其制备方法和应用
CN105198982B (zh) 基于il-6的抗原表位及其应用
CN109748952B (zh) 辅助性表位肽及其应用
Shen et al. DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice
CA3001725C (en) Modified h7 hemaglutinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
KR20240163165A (ko) 에피토프의 조합과 그의 용도, 백신 구조물, 면역 반응의 유도 방법 에피토프의 식별 방법
CN117396493A (zh) 氨基酸、核苷酸和表达它们的载体及其在预防沙贝病毒感染中的用途